Effect of high-dose vitamin D3 on 28-day mortality in adult critically ill patients with severe vitamin D deficiency: a study protocol of a multicentre, placebo-controlled double-blind phase III RCT (the VITDALIZE study).

Amrein, Karin; Parekh, Dhruv; Westphal, Sabine; Preiser, Jean-Charles; Berghold, Andrea; Riedl, Regina; Eller, Philipp; Schellongowski, Peter; Thickett, David; Meybohm, Patrick (2019). Effect of high-dose vitamin D3 on 28-day mortality in adult critically ill patients with severe vitamin D deficiency: a study protocol of a multicentre, placebo-controlled double-blind phase III RCT (the VITDALIZE study). BMJ open, 9(11), e031083. BMJ Publishing Group 10.1136/bmjopen-2019-031083

[img]
Preview
Text
2019 - Amrein - BMJ Open - PMID 31722941.pdf - Published Version
Available under License Creative Commons: Attribution-Noncommercial (CC-BY-NC).

Download (485kB) | Preview

INTRODUCTION

Observational studies have demonstrated an association between vitamin D deficiency and increased risk of morbidity and mortality in critically ill patients. Cohort studies and pilot trials have suggested promising beneficial effects of vitamin D replacement in the critical ill, at least in patients with severe vitamin D deficiency. As vitamin D is a simple, low-cost and safe intervention, it has potential to improve survival in critically ill patients.

METHODS AND ANALYSIS

In this randomised, placebo-controlled, double-blind, multicentre, international trial, 2400 adult patients with severe vitamin D deficiency (25-hydroxyvitamin D≤12 ng/mL) will be randomised in a 1:1 ratio by www.randomizer.at to receive a loading dose of 540 000 IU cholecalciferol within 72 hours after intensive care unit (ICU) admission, followed by 4000 IU daily for 90 days or placebo. Hypercalcaemia may occur as a side effect, but is monitored by regular checks of the calcium level. The primary outcome is all-cause mortality at 28 days after randomisation. Secondary outcomes are: ICU, hospital, 90-day and 1-year mortality; hospital and ICU length of stay, change in organ dysfunction on day 5 as measured by Sequential Organ Function Assessment (SOFA) score, number of organ failures; hospital and ICU readmission until day 90; discharge destination, self-reported infections requiring antibiotics until day 90 and health-related quality of life. Recruitment status is ongoing.

ETHICS AND DISSEMINATION

National ethical approval was obtained by the Ethics Committee of the University of Graz for Austria, Erasme University Brussels (Belgium) and University Hospital Frankfurt (Germany), and will further be gained according to individual national processes. On completion, results will be published in a peer-reviewed scientific journal. The study findings will be presented at national and international meetings with abstracts online.

TRIAL REGISTRATION

NCT03188796, EudraCT-No: 2016-002460-13.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Intensive Care, Emergency Medicine and Anaesthesiology (DINA) > Clinic of Intensive Care

Subjects:

600 Technology > 610 Medicine & health

ISSN:

2044-6055

Publisher:

BMJ Publishing Group

Language:

English

Submitter:

Isabelle Arni

Date Deposited:

17 Dec 2019 09:15

Last Modified:

24 Feb 2021 01:03

Publisher DOI:

10.1136/bmjopen-2019-031083

PubMed ID:

31722941

Additional Information:

Der Autor Jakob Stephan war Mitglied der unter den Autoren aufgeführten VITDALIZE Collaboration Group. Siehe diesbezüglich auch im Artikel auf Seite 7, Stichwort "Collaborators".

Uncontrolled Keywords:

critically ill patients intensive care unit severe vitamin D deficiency vitamin D vitamin D supplementation

BORIS DOI:

10.7892/boris.136882

URI:

https://boris.unibe.ch/id/eprint/136882

Actions (login required)

Edit item Edit item
Provide Feedback